OC
AMED

Oppenheimer & Co’s Amedisys AMED Stock Holding History

Oppenheimer & Co’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,655
Closed -$802K – 1407
2022
Q1 		$802K Buy
4,655
+12
+0.3% +$1.79K 0.01% 829
2021
Q4 		$751K Sell
4,643
-1,727
-27% -$278K 0.01% 893
2021
Q3 		$949K Buy
6,370
+1,158
+22% +$241K 0.02% 762
2021
Q2 		$1.28M Buy
5,212
+56
+1% +$14.7K 0.02% 659
2021
Q1 		$1.36M Sell
5,156
-61
-1% -$17.2K 0.03% 592
2020
Q4 		$1.53M Sell
5,217
-87
-2% -$22.3K 0.03% 512
2020
Q3 		$1.25M Buy
5,304
+239
+5% +$54.3K 0.03% 508
2020
Q2 		$1.01M Sell
5,065
-8
-0.2% -$1.49K 0.03% 568
2020
Q1 		$931K Buy
5,073
+551
+12% +$98K 0.03% 548
2019
Q4 		$755K Buy
+4,522
New +$673K 0.02% 709
2019
Q3 		– Sell
-1,908
Closed -$232K – 1260
2019
Q2 		$232K Buy
+1,908
New +$226K 0.01% 1120

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Oppenheimer & Co's AMED Position: Q2 2022 in Review

Oppenheimer & Co sold out of Amedisys (AMED) in Q2 2022, closing a stake of 4,655 shares — an estimated $802K sold.

Oppenheimer & Co first reported a position in AMED in Q2 2019 and held it in 11 quarters. The position peaked at $1.53M in Q4 2020. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

  • Oppenheimer & Co reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 4,655 Amedisys shares in Q2 2022, an estimated $802K.
  • Oppenheimer & Co first reported a position in Amedisys in Q2 2019 and held it in 11 quarters.
  • Oppenheimer & Co's Amedisys position peaked at $1.53M in Q4 2020.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Oppenheimer & Co's 13F filing for Q2 2022, filed 8 Aug 2022.